Search Results

Biotech Beach

Adagene to Present at Investor Conferences in June

Adagene Inc. today announced its participation in multiple investor conferences in June 2024.

May 22, 2024

·

4 min read

Business

Adagene to Participate in Investor Conferences in September

August 29, 2024

·

2 min read

Business

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today reported financial results for the full year 2023 and provided corporate updates.

March 29, 2024

·

22 min read

Biotech Beach

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

Adagene Inc. today announced its participation in the Leerink Partners Global Biopharma Conference 2024, taking place March 11-13 in Miami, Florida.

February 27, 2024

·

1 min read

Business

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Adagene Inc. announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board.

March 7, 2024

·

5 min read

Business

Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update

July 29, 2024

·

21 min read

Press Releases

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

October 9, 2024

·

4 min read

Press Releases

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

November 8, 2024

·

9 min read

Biotech Beach

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced data from its presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium, taking place January 18-20 in San Francisco.

January 16, 2024

·

6 min read

Biotech Bay

Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium

Adagene Inc. announced a poster presentation at the American Society of Clinical Oncology 2024 Gastrointestinal Cancers Symposium, taking place January 18-20 in San Francisco.

January 4, 2024

·

3 min read